USFDA Issues 7 Observations to Dr. Reddy's Biologics Facility
Summary
Dr. Reddy's Laboratories received a Form 483 with seven observations from the USFDA following an inspection of its biologics manufacturing facility, requiring timely remediation.
Key Events
-
USFDA Inspection Completed
The USFDA concluded a Pre-License Inspection (PLI) at the company's biologics manufacturing facility in Bachupally, Hyderabad, from June 16 to June 25, 2026.
-
Form 483 Issued with 7 Observations
The company received a Form 483 with seven observations, indicating potential violations of regulatory standards at the facility.
-
Follows Prior Inspections
This inspection and subsequent Form 483 are a continuation of earlier regulatory scrutiny, with previous disclosures made in October 2023 and September 2025.
Analysis
The USFDA completed a Pre-License Inspection at Dr. Reddy's biologics manufacturing facility, issuing a Form 483 with seven observations. This is a significant regulatory development, especially as it follows previous inspections in 2023 and 2025. The company must address these observations within the stipulated timeline to avoid potential delays in product approvals or further regulatory actions, which could impact its biologics pipeline and manufacturing capabilities.
At the time of this filing, RDY was trading at $15.59 on NYSE in the Life Sciences sector, with a market capitalization of approximately $11.9B. The 52-week trading range was $12.19 to $15.67. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.